专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US07691837B2 Pyrrole derivatives as antimycobacterial compounds 失效
公开(公告)号：US07691837B2
公开(公告)日：2010-04-06
申请号：US10497615
申请日：2002-09-20
申请人： Sudershan Kumar Arora , Neelima Sinha , Sanjay Jain , Ram Shankar Upadhayaya , Gourhari Jana , Shankar Ajay , Rakesh Kumar Sinha
发明人： Sudershan Kumar Arora , Neelima Sinha , Sanjay Jain , Ram Shankar Upadhayaya , Gourhari Jana , Shankar Ajay , Rakesh Kumar Sinha
IPC分类号： A01N43/00 , A01N43/40 , A61K31/33 , A61K31/55 , A61K31/497 , A61K31/435 , C07D223/00 , C07D243/00 , C07D241/04 , C07D295/00 , C07D213/00
CPC分类号： C07D207/335 , C07D207/32 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D417/06
摘要： Novel pyrrole derivatives of formula (I) and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).

32. 发明申请

US20090306016A1 FATTY ACID AMIDE HYDROLASE INHIBITORS 有权
标题翻译：脂肪酸酰胺水解酶抑制剂
公开(公告)号：US20090306016A1
公开(公告)日：2009-12-10
申请号：US12309661
申请日：2007-07-27
申请人： Alexandros Makriyannis , Spyridon P. Nikas , Shakiru O. Alapafuja , Vidyanand G. Shukla
发明人： Alexandros Makriyannis , Spyridon P. Nikas , Shakiru O. Alapafuja , Vidyanand G. Shukla
IPC分类号： A61K31/695 , C07C315/00 , A61K31/10 , C07C49/00 , A61K31/12 , C07C261/00 , A61K31/27 , C07D211/70 , A61K31/44 , C07D213/00 , C07D271/10 , C07D275/02 , A61K31/4245 , A61K31/428 , C07F5/02
CPC分类号： C07D213/75 , C07C17/16 , C07C45/41 , C07C45/44 , C07C45/45 , C07C45/673 , C07C49/233 , C07C49/255 , C07C49/84 , C07C69/712 , C07C69/738 , C07C271/12 , C07C271/14 , C07C271/16 , C07C271/24 , C07C271/38 , C07C271/58 , C07C309/68 , C07C309/81 , C07C309/82 , C07C2601/14 , C07C2603/74 , C07D213/30 , C07D213/40 , C07D213/50 , C07D263/56 , C07D271/10 , C07D275/06 , C07D277/64 , C07C22/04 , C07C47/277 , C07C47/575 , C07C49/83
摘要： Disclosed are compounds of formula R—X—Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CB1i and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response.
摘要翻译：公开了可用于抑制脂肪酸酰胺水解酶（FAAH）作用的式R-X-Y的化合物。脂肪酸酰胺水解酶（FAAH）的抑制将通过FAAH水解减缓内源性大麻素配体的正常降解和失活，并允许更高水平的那些内源性大麻素能配体保持存在。这些更高水平的内源性大麻素配体提供对大麻素CB1i和CB2受体的增加的刺激，并产生与大麻素受体活化相关的生理作用。与其中脂肪酰胺水解酶（FAAH）作用被热抑制的系统相比，它们还将增强其他外源性大麻素配体的作用，并使它们以较低的浓度产生它们的作用。因此，通过脂肪酰胺水解酶（FAAH）抑制内源性大麻素配体失活的化合物可能增加内源性大麻素的含量，从而增加大麻素受体的活化。因此，化合物不能直接调节大麻素受体，而是通过增加内源性大麻素配体的水平来间接刺激大麻素受体的作用。它还可以增强其它外源性大麻素能配体的作用和持续时间，以引发大麻素应答。

33. 发明授权

US07446210B2 Factor Xa compounds 有权
标题翻译：因子Xa化合物
公开(公告)号：US07446210B2
公开(公告)日：2008-11-04
申请号：US11257208
申请日：2005-10-24
申请人： Tianbao Lu , Tho V. Thieu , Yu-Kai Lee , Daniel J. Parks , Thomas P. Markotan , Wenxi Pan , Karen L. Milkiewicz , Mark R. Player
发明人： Tianbao Lu , Tho V. Thieu , Yu-Kai Lee , Daniel J. Parks , Thomas P. Markotan , Wenxi Pan , Karen L. Milkiewicz , Mark R. Player
IPC分类号： C07D207/00 , C07D213/00 , C07D231/00 , C07D231/54 , C07D239/02 , C07D241/04 , C07D265/28 , C07D295/00 , C07D487/00
CPC分类号： C07D413/14 , C07D231/56 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D409/14 , C07D413/04 , C07D417/10
摘要： The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.
摘要翻译：本发明涉及式I的新型化合物及其形式和药物组合物，以及其作为因子Xa抑制剂的用途。

34. 发明授权

US07442796B2 Compounds for the treatment of metabolic disorders 有权
标题翻译：用于治疗代谢紊乱的化合物
公开(公告)号：US07442796B2
公开(公告)日：2008-10-28
申请号：US10554586
申请日：2004-04-20
申请人： Shalini Sharma , Reid W. von Borstel
发明人： Shalini Sharma , Reid W. von Borstel
IPC分类号： C07D213/00 , C07D211/70 , C07C69/76 , C07C229/00
CPC分类号： A61K31/235 , A61K31/19 , A61K31/24
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0 to 4; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalendy bound to the remainder of the compound of formula (I) by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
摘要翻译：公开了可用于治疗诸如胰岛素抵抗综合征，糖尿病，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化的各种代谢疾病的药剂。式（I）其中n为1或2; m为0〜4; q为0或1; t为0或1; R 2是具有1至3个碳原子的烷基; R 3是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; A是未取代的或被1或2个选自：卤素，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基取代的苯基; 或具有3至6个环碳原子的环烷基，其中环烷基是未取代的或一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式（I）化合物的其余部分共价结合; R 1是氢或具有1或2个碳原子的烷基。或者，当R 1是氢时，生物活性剂可以是式（I）化合物的药学上可接受的盐。

35. 发明授权

US07414132B2 Opioid receptor antagonists 失效
标题翻译：阿片受体拮抗剂
公开(公告)号：US07414132B2
公开(公告)日：2008-08-19
申请号：US10581178
申请日：2004-12-15
申请人： Marta Garcia De La Torre , Nuria Diaz Buezo , Prabhakar Kondaji Jadhav , Charles Howard Mitch , Concepcion Pedregal-Tercero
发明人： Marta Garcia De La Torre , Nuria Diaz Buezo , Prabhakar Kondaji Jadhav , Charles Howard Mitch , Concepcion Pedregal-Tercero
IPC分类号： C07D213/00 , C07D231/56 , C07D261/20 , C07D413/00 , C07D498/00
CPC分类号： C07D213/78 , C07D213/80 , C07D213/82 , C07D231/56 , C07D261/20 , C07D401/04 , C07D409/14 , C07D413/12 , C07D413/14
摘要： A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3′, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
摘要翻译：式（I）化合物; 其中X 1至X 10，R 1至R 7的变量X 1至R 7包括R 3' / SUP>，E，W，v，y，z，A和B如上所述，或其药学上可接受的盐，溶剂合物，对映异构体，外消旋物，非对映体或其混合物，可用于治疗，预防或改善肥胖症和相关疾病被公开。

36. 发明授权

US07351865B2 Synthesis of sterically hindered secondary aminoether alcohols from acid anhydride and/or acid halide and sulfur trioxide 有权
标题翻译：由酸酐和/或酰基卤和三氧化硫合成空间位阻的仲氨基醚醇
公开(公告)号：US07351865B2
公开(公告)日：2008-04-01
申请号：US10587199
申请日：2005-02-01
申请人： Michael Siskin , Alan Roy Katritzky , Kostyantyn Mykolayevich Kirichenko , Adeana Richelle Bishop , Christine Nicole Elia
发明人： Michael Siskin , Alan Roy Katritzky , Kostyantyn Mykolayevich Kirichenko , Adeana Richelle Bishop , Christine Nicole Elia
IPC分类号： C07C209/00 , C07D213/00 , C07D213/02 , C07D213/08
CPC分类号： C07C213/08 , C07C217/08
摘要： Severely sterically hindered secondary aminoether alcohols are prepared by reacting acid anhydrides or organic carboxylic acid halides with SO3 to yield a sulfonic carboxylic anhydride compound which is then reacted with a dioxane to cleave the ring of the dioxane yielding a cleavage product which is then aminated with an alkylamine and hydrolyzed with a base to yield the severely sterically hindered secondary aminoether alcohol.
摘要翻译：通过使酸酐或有机羧酸卤化物与SO 3 3反应制备严格的空间位阻的仲氨基醚醇，得到磺酸酐化合物，然后与二恶烷反应以切割二烷环，产生裂解产物然后用烷基胺胺化并用碱水解，得到严重位阻的仲氨基醚醇。

37. 发明授权

US07351825B2 Cyclopropane compounds and pharmaceutical use thereof 失效
标题翻译：环丙烷化合物及其药物用途
公开(公告)号：US07351825B2
公开(公告)日：2008-04-01
申请号：US11011773
申请日：2004-12-15
申请人： Takashi Inaba , Julia Haas , Makoto Shiozaki , Nicole M. Littmann , Katsutaka Yasue , Steven W. Andrews , Atushi Sakai , Andrew M. Fryer , Takafumi Matsuo , Ellen R. Laird , Akira Suma , Yuichi Shinozaki , Yoshikazu Hori , Hiroto Imai , Tamotsu Negoro
发明人： Takashi Inaba , Julia Haas , Makoto Shiozaki , Nicole M. Littmann , Katsutaka Yasue , Steven W. Andrews , Atushi Sakai , Andrew M. Fryer , Takafumi Matsuo , Ellen R. Laird , Akira Suma , Yuichi Shinozaki , Yoshikazu Hori , Hiroto Imai , Tamotsu Negoro
IPC分类号： C07D265/00 , C07D295/00 , C07D237/00 , C07D409/00 , C07D411/00 , C07D217/00 , C07D211/00 , C07D213/00 , C07D271/00 , C07D413/00 , C07D498/00 , C07D277/00 , C07D257/00 , C07D233/00 , C07D231/00 , C07D207/00 , C07D333/00 , C07D307/00 , C07D303/00 , C07D309/00 , C07D311/00
CPC分类号： C07C311/29 , C07C311/13 , C07C311/20 , C07C311/22 , C07C311/46 , C07C2601/02 , C07C2601/14 , C07C2603/08 , C07C2603/18 , C07C2603/30 , C07D205/04 , C07D207/48 , C07D209/44 , C07D211/58 , C07D211/96 , C07D213/18 , C07D213/65 , C07D213/71 , C07D213/74 , C07D213/81 , C07D213/82 , C07D217/08 , C07D231/12 , C07D233/64 , C07D237/12 , C07D239/22 , C07D243/08 , C07D257/04 , C07D261/08 , C07D271/06 , C07D271/107 , C07D277/26 , C07D277/36 , C07D277/82 , C07D295/26 , C07D307/79 , C07D307/91 , C07D333/18 , C07D333/34 , C07D333/36 , C07D333/38 , C07D333/62 , C07D401/04 , C07D409/04 , C07D409/12 , C07D413/04 , C07D417/04 , C07D417/12 , C07D471/04 , C07D487/04 , C07D513/04
摘要： The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供具有聚集蛋白聚糖蛋白聚糖酶抑制活性和MMP-13抑制活性的化合物，可用作骨关节炎，类风湿性关节炎等的治疗剂，更具体而言，可以使用式（1）的环丙烷化合物：其中R 1 是 - （CH 2）2 -X-（CH 2）n - SUP> 1等，其中m和n相同或不同，并且各自为0至6，X为单键等，而A 1为取代的C _{3-14个烃环基等; R 2和R 3相同或不同，并且各自为氢原子， - （CH 2）2 N 其中p和q为 - （CH 2）2 - - - - CH 2 - 相同或不同，并且各自为0至6，X 1为单键等，而A 2为任选取代的C 3-14烷基，烃环等; R 4是-CO 2 R 9等，其中R 9是氢原子等。 ; 和R 20和R 21相同或不同，各自为氢原子， - （CH 2 CH 2）m 12 其中m12和m12（其中m12和m12）相同或不同，各自为0至6，X 12为单键等，R 30为氢原子等; 或其前药或其药学上可接受的盐。}

38. 发明申请

US20080004261A1 CGRP receptor antagonists 有权
标题翻译： CGRP受体拮抗剂
公开(公告)号：US20080004261A1
公开(公告)日：2008-01-03
申请号：US11818224
申请日：2007-06-13
申请人： Corey Gutierrez , Andreas Termin , Sara Hadida-Ruah , Pramod Joshi , Daniele Bergeron , Sanghee Yoo , Hayley Binch , Jon Come , Jingrong Cao , Suganthi Nanthakumar
发明人： Corey Gutierrez , Andreas Termin , Sara Hadida-Ruah , Pramod Joshi , Daniele Bergeron , Sanghee Yoo , Hayley Binch , Jon Come , Jingrong Cao , Suganthi Nanthakumar
IPC分类号： A61K31/551 , A61K31/426 , A61K31/437 , A61K31/44 , C07D213/00 , C07D239/70 , C07D277/00 , C07D243/04 , C07D221/00 , A61K31/4427 , A61K31/445 , A61K31/517
CPC分类号： C07D277/14 , C07D417/06 , C07D417/14 , C07D471/04 , C07D471/10 , C07D498/10 , C07D513/10
摘要： The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
摘要翻译：本发明涉及CGRP受体拮抗剂，其药物组合物及其用于治疗CGRP受体介导的疾病和病症的方法。

39. 发明授权

US07186835B2 Composition comprising amino-imine compounds 失效
标题翻译：组合物包含氨基 - 亚胺化合物
公开(公告)号：US07186835B2
公开(公告)日：2007-03-06
申请号：US11017147
申请日：2004-12-20
申请人： Alexander Zak Bradley , Jeffery Scott Thompson , David Lincoln Thorn
发明人： Alexander Zak Bradley , Jeffery Scott Thompson , David Lincoln Thorn
IPC分类号： C07D213/00
CPC分类号： C07D213/74 , C07C251/12 , C07C251/16 , C23C16/18 , C23C16/45525 , C23C16/45553 , H01L21/288 , H01L21/3141 , Y10T428/31504
摘要： The composition relates to amino-imine compounds used in the formation of 1,3-diimine copper complexes for deposition of copper films.
摘要翻译：该组合物涉及用于形成用于沉积铜膜的1,3-二亚胺铜络合物的氨基 - 亚胺化合物。

40. 发明授权

US07163938B2 Substituted carboxamides 失效
标题翻译：取代的甲酰胺
公开(公告)号：US07163938B2
公开(公告)日：2007-01-16
申请号：US10415756
申请日：2001-11-14
申请人： David Kent Herron , Sajan Joseph , Angela Lynn Marquart , John Joseph Masters , David Mendel , Gerald Floyd Smith , Philip Parker Waid , Michael Robert Wiley , Ying Kwong Yee
发明人： David Kent Herron , Sajan Joseph , Angela Lynn Marquart , John Joseph Masters , David Mendel , Gerald Floyd Smith , Philip Parker Waid , Michael Robert Wiley , Ying Kwong Yee
IPC分类号： A61P7/00 , A61K31/44 , A61K31/55 , C07D213/00 , C07D401/12
CPC分类号： C07D213/75 , C07D213/81 , C07D401/12 , C07D401/14
摘要： This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
摘要翻译：本申请涉及如本文所定义的式I化合物（或其药学上可接受的盐），其药物组合物及其作为因子Xa抑制剂的用途，以及其制备方法及其中间体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式